Schering Aktiengesellschaft

Hoffmann-la Roche Inc.

Other

Schering, A.g. Patentabteilung

Rudolf Wiechert

Henry Laurent

Helmut Hofmeister

Klaus Annen

Ulrich Kerb

Ulrich Eder

Gerhard Sauer

Gregor Haffer

Dieter Bittler

Walter Elger

Marcel Muller

Andor Furst

Gunter Neef

Sybille Beier

Leo Alig

Karl Petzoldt

Klaus Nickisch

David A Henderson

Jurgen Ruppert

Wolfgang Losert

Hans Wendt

Hermann Steinbeck

Eckhard Ottow

Klaus Kieslich

Yukishige Nishino

Klaus Prezewowsky

Alfred Weber

Jorge Casals-Stenzel

Mario Kennecke

Robert C Nickolson

Peter Keller

Guenter Neef

Joachim-Friedrich Kapp

Manfred Albring

Otto Engelfried

Annerose Schleusener

Helmut Hauser

Rolf Bohlmann

Helmut Wachtel

Peter Esperling

Ralph Rohde

James R Bull

Rudolf Mueller

Paul E Schulze

Jurg Albert Gutzwiller

Juergen Ruppert

Gerald Kirsch

Wolfgang Kehr

Reinhard Horowski

Dieter Palenschat

Gert Paschelke

Michael Topert

Friedmund Neumann

Kunhard Pollow

Michael Toepert

Peter Jungblut

Andreas Huth

Dieter Seidelmann

Ralph Schmiechen

Martin Haberey

Herbert H Schneider

Karl-Heinrich Fritzemeier

Arwed Cleve

Martin Schneider

David N Stephens

Helmut Dahl

Henning Koch

Rudolf Muller

Hermann Kunzer

Peter Fuchs

Hans-Jorg Vidic

Rainer Philippson

Hans Peter Lorenz

Peter Klaus Mengel

Ernst Schottle

Bernhard Krieger

Erich Gerhards

Heinz Matthes

Karl-Heinz Kolb

Bernhard Manz

Hans-Joerg Grill

Alfred Popper

Manfred Stahnke

Joachim F Kapp

Yukeshige Nishino

Klaus Nickish

Helmut Schroeder

Russell I Thomson

Hans J Grill

Hans-Peter Lorenz

Juergen Bardenhagen

Klaus Mengel

Dihydrospirorenone, ##STR1## preferably together with an estrogen, can be used for the production of a pharmaceutical agent suitable for treatment of hormonal irregularities during premenopause (menstruation stabilization), for hormonal substitution therapy during menopause, for treatment of androgen-induced disorders and/or for contraception.

Dihydrospirorenone as an antiandrogen

A 14.alpha.,17.alpha.-bridged estratriene of formula I ##STR1## wherein (a) OR.sup.3 is in .alpha.-position

14.alpha., 17.alpha.-ethano-16.alpha.-hydroxy-estratrienes

A process of cyclizing compounds of formula II ##STR1## wherein K, V', R.sup.1 and 1 are as herein defined, is described whereby a compound of formula IVa is produced ##STR2## wherein K, V', R.sup.1, Q, S and 1 are as herein defined. The compounds of formula IVa are useful intermediates in the production of compounds of formula I ##STR3## wherein ring A, B, G, V, Z, R.sup.1 and R.sup.2 are as herein defined.

Process for preparing 19,11.beta.-bridged steroids

Process for the production of 10.beta.-H-steroids

9.alpha.-hydroxy-19,11.beta.-bridged steroids, their production and

Disclosed are novel 14,17.alpha.-etheno- and -ethanoestratrienes according to general Formula I ##STR1## wherein X is a --CH.sub.2 --CH.sub.2 or ##STR2## R.sup.1 is a hydrogen atom, a C.sub.1 - to C.sub.15 -acyl, benzoyl, C.sub.1 - to C.sub.15 -alkyl, C.sub.3 - to C.sub.9 -cycloalkyl or alkylcycloalkyl group, and

14,17.alpha.-etheno- and -ethanoestratrienes, processes for the

##STR1## New 14.alpha.,17.alpha.-ethano-estratrienes of general formula (I) wherein R.sup.1 is a hydrogen atom, an alkyl or acyl group with 1 to 12 carbon atoms, R.sup.2 is a hydrogen atom or a methyl group, R.sup.3 is a hydrogen atom or an acyl group with 1 to 12 carbon atoms and (a) is either (II) or (III), where R.sup.4 is an alkyl residue in the .alpha. or .beta. position with 1 to 8 carbon atoms or an .alpha.,.beta.-alkenyl residue which may contain several double bonds or an .alpha.,.beta.-alkinyl residue, both with 2 to 8 carbon atoms, are described. Also described is a process for producing them. These new compounds have a marked oestrogenic activity.

14.alpha.,17.alpha.-ethanoestratrienes

17-halomethylene estratrienes of Formula I ##STR1## wherein R.sub.1 is hydrogen, a methyl or acyl group, and

17-halomethylene estratrienes

New 19,11.beta.-bridged steroids of the general formula I ##STR1## where R.sup.1 stands for a methyl or ethyl radical,

19,11 .beta.-bridged steroids, their manufacture and pharmaceutical

11 .beta.-(4-isopropenylphenyl)-estra-4,9-dienes of general Formula I ##STR1## wherein X is an oxygen atom or a hydroxyimino grouping ##STR2## R.sup.1 is a hydrogen atom or a methyl group, R.sup.2 is a hydrogen atom or an acyl residue of 1-10 carbon atoms,

.beta.-(4-isopropenylphenyl)estra-4,9-dienes, their production, and

A pharmaceutical preparation for treating menopausal symptoms, estrogen deficiency and hormone-dependent tumors, and for use as a contraceptive, comprises a compound of formula I ##STR1## wherein R.sub.1 is hydrogen, methyl, a tetrahydropyranyl group or an acyl group and

17-methylene- and 17-ethylidene-estratrienes

Known pregnane derivatives are prepared by esterification of know androstane derivatives to give new esters of Formula III ##STR1## wherein  in each case symbolizes a single bond or a double bond,

Process for the preparation of pregnane derivatives

Estrane and androstane derivatives of formula I ##STR1## wherein X is bromine, iodine, triphenyltin or trialkyltin of 1 to 6 carbon atoms per alkyl radical,

Estrane and androstane derivatives, process for producing them and

A process for the production of 17.alpha.-ethinyl-17.beta.-hydroxy-18-methyl-4,15-estradien-3-one is described comprising reacting a 17-enolester of formula II ##STR1## wherein R.sub.1 represents an alkyl radical with 1-3 carbon atoms and

Process for the production of

6.alpha.-methylhydrocortisones of Formula I ##STR1## wherein R.sub.1 is alkanoyl of 2-6 carbon atoms or benzoyl and

Antiinflammatory 6 alpha-methylhydrocortisones

Growing community of inventors

Berlin, Germany

Rudolf Wiechert